^(125)I粒子植入联合化疗治疗结直肠癌术后肝转移的临床研究  

^(125)I Seed Implantation Combined with Chemotherapy for Colorectal Cancer with Postoperative Liver Metastasis

作　　者：任庆[1] 熊锐华[1] 田秀荣[1] 鲍忠平[1] 唐新云[1] 罗克品[1] 

机构地区：[1]中国人民解放军第一八一医院肿瘤治疗中心,广西桂林541002

出　　处：《肿瘤防治研究》2014年第6期653-656,共4页Cancer Research on Prevention and Treatment

摘　　要：目的探讨放射性125I粒子植入联合化疗治疗结直肠癌术后肝转移的临床疗效与安全性。方法52例结直肠癌术后肝转移的患者随机分为两组,其中27例采用125I粒子植入肝脏转移瘤病灶,并联合FOLFIRI方案(伊立替康+氟尿嘧啶+亚叶酸钙)化疗(治疗组),其余25例单用FOLFIR方案化疗(对照组),对比两组患者的近、远期疗效与不良反应。结果治疗组有效率为74.1%,对照组有效率为40.0%,治疗组中位无进展时间为15.6月,对照组中位无进展时间为10.2月,差异均有统计学意义。对照组患者出现不同程度的消化道反应、肝功能损害、骨髓抑制反应,治疗组患者除上述反应外,部分合并疼痛、低热,均可耐受。结论放射性125I粒子植入联合化疗治疗结直肠癌术后肝转移近、远期疗效肯定,不良反应可耐受。Objective To observe the clinical therapeutic effect and safety of 125I radioactive seed implantation combined chemotherapy on colorectal cancer with postoperative liver metastasis. Methods A total of 52 colorectal cancer patients with postoperative liver metastasis were randomly divided into treatment and control group. Treatment group was treated with 125I radioactive seed combined with FOLFIRI regimen(Irinotecan+5-Fu+LV) and control group was treated with FOLFIRI regimen. The clinical efficacy and adverse reaction were compared between two groups. Results The response rate and median time to progression of treatment group were 74.1% and 15.6 months, and those of control group were 40.0% and 10.2 months, with significantly statistical difference. The main adverse reactions, such as gastrointestinal reaction, liver function damage and myelosuppression at different levels, were found in both group, moreover, patients in treatment group suffered endurable pain and low-grade fever. Conclusion The clinical therapeutic effect of 125I radioactive seed implantation combined with chemotherapy in colorectal cancer with postoperative liver metastasis is definite and adverse reactions are endurable.

关 键 词：结直肠癌 肝转移 125I粒子 植入治疗 化学治疗 

分 类 号：R73[医药卫生—肿瘤]